Physician profile
Harmeet Singh
NPI 1639197437
$3,408.68
in general payments reported to CMS, 2019-2025
28 companies · $437 in 2025
The $437 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $448 · 2021: $536 · 2022: $431 · 2023: $449 · 2024: $540 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,426.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,441.29 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Sunovion Pharmaceuticals INC. | $326.52 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $300.40 | 2019-2022 | |
| Mylan Specialty L.P. | $222.00 | 2019-2024 | Yupelri |
| Medtronic, INC. | $158.80 | 2021 | |
| Gilead Sciences, INC. | $124.98 | 2024 | Biktarvy |
| Astrazeneca Pharmaceuticals LP | $118.20 | 2023-2025 | Farxiga, Airsupra |
| Inspire Medical Systems, INC. | $99.92 | 2024-2025 | Inspire |
| Genzyme Corporation | $64.76 | 2024-2025 | |
| Exact Sciences Corporation | $62.10 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $58.13 | 2021 | |
| Lilly USA, LLC | $48.05 | 2022-2024 | Mounjaro |
| Pfizer INC. | $47.08 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $44.50 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $43.27 | 2023 | Nuedexta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $37.59 | 2022-2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $36.16 | 2024 | Dupixent |
| Arbor Pharmaceuticals, INC. | $25.77 | 2021 | |
| Philips North America LLC | $21.28 | 2025 | Vest Therapy Und |
| Insmed, INC. | $16.24 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.93 | 2019 | |
| Eisai INC. | $14.92 | 2021 | |
| Mallinckrodt Enterprises LLC | $14.62 | 2019 | |
| Endo Pharmaceuticals INC. | $14.32 | 2020 | |
| Electromed, INC. | $14.28 | 2024 | Smartvest |
| Janssen Pharmaceuticals, INC | $13.45 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.12 | 2021 | |
| Amarin Pharma, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harmeet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.